Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 28, 2021

Autoimmunity and Benefit/Risk Profile of Alemtuzumab for Multiple Sclerosis

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Mult. Scler. 2021 Dec 09;[EPub Ahead of Print], AJ Coles, JL Jones, P Vermersch, A Traboulsee, AD Bass, A Boster, A Chan, G Comi, Ó Fernández, G Giovannoni, E Kubala Havrdova, C LaGanke, X Montalban, C Oreja-Guevara, F Piehl, H Wiendl, T Ziemssen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading